Recent Transactions

24-Mar-17
$1.6 billion
U.S.A. flag
Target: 

Advised the Official Committee of Unsecured Creditors on CHC’s Chapter 11 proceedings

flag not available

Greenhill advised the Official Committee of Unsecured Creditors of CHC, a leading helicopter flight services company, on CHC’s Chapter 11 proceedings

23-Feb-17
$1.1 billion
U.S.A. flag
Target: 

Natural Resource Partners L.P.

flag not available

Advised Natural Resource Partners L.P., a publicly-traded master limited partnership that owns, manages and leases mineral properties in the United States, on a series of recapitalization transactions including the extension of NRP’s near-term debt maturities and the issuance of $250mm of new preferred equity capital to funds managed by Blackstone Tactical Opportunities and from several affiliates of GoldenTree Asset Management L.P.

10-Feb-17
Pending
$2.0 billion
U.S.A. flag
Target: 

Immunomedics, Inc. lead product candidate, IMMU-132

U.S.A. flag
Acquiror: 
Seattle Genetics

Advising Immunomedics, Inc. on the exclusive global licensing agreement with Seattle Genetics for the rights to develop, manufacture and commercialize sacituzumab govitecan (“IMMU-132”), an antibody-drug conjugate (ADC) targeted to TROP-2, which is expressed in several solid tumors, including cancers of the breast, lung and bladder

25-Jan-17
Pending
$325 million
U.S.A. flag
Target: 

Ad Hoc Group of Senior Secured Noteholders

flag not available

Advising the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.

10-Jan-17
$204 million
U.S.A. flag
Target: 

Derma Sciences, Inc.

U.S.A. flag
Acquiror: 
Integra LifeSciences Holdings Corporation

Advising Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology

09-Jan-17
$465 million
U.S.A. flag
Target: 

Palatin Technologies, Inc. lead product candidate, Rekynda

U.S.A. flag
Acquiror: 
AMAG Pharmaceuticals, Inc.

Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.

12-Dec-16
$NA
U.S.A. flag
Target: 

Gradifi, Inc.

U.S.A. flag
Acquiror: 
First Republic Bank

Advised First Republic Bank, a provider of private banking, private business banking and private wealth management services, on the acquisition of Gradifi, a Boston-based technology and service platform used by employers to make direct contributions to employees’ student loans

06-Dec-16
Pending
$1.8 billion
U.K., German flags
Target: 

Host Europe Group

U.S.A. flag
Acquiror: 
GoDaddy

Advising GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe

22-Nov-16
$NA
U.S.A. flag
Target: 

Adams Media

U.S.A. flag
Acquiror: 
Simon & Schuster

Advised F+W Media, a content and e-commerce company, on the divestment its consumer book publishing business, Adams Media, to Simon & Schuster, a division of CBS Corporation

14-Nov-16
$748 million
U.S.A. flag
Target: 

Peacock Foods

uk.gif
Acquiror: 
Greencore Group plc

Advising Greencore Group plc, a leading international manufacturer of convenience foods based in Ireland, on the proposed acquisition of Peacock Foods, a manufacturing partner for consumer packaged goods companies in the US.

03-Nov-16
Pending
$3.3 billion
U.S.A. flag
Target: 

Metaldyne Performance Group, Inc.

U.S.A. flag
Acquiror: 
American Axle & Manufacturing Holdings, Inc.

Advising American Axle & Manufacturing Holdings, Inc., a leading manufacturer of driveline and drivetrain systems and related components and metal-formed products, on the acquisition of Metaldyne Performance Group, Inc., a provider of highly-engineered lightweight components for use in powertrain and suspension applications for the global light, commercial and industrial vehicle markets

03-Nov-16
$NA
switzerland.gif
Target: 

Fragrance Resources Group

U.S.A. flag
Acquiror: 
International Flavors & Fragrances Inc.

Advising IFF, one of the world’s largest flavors and fragrances businesses, on the acquisition of Fragrance Resources Group, a family-owned fragrance company headquartered in Switzerland

02-Nov-16
Pending
$NA
U.S.A. flag
Target: 

IAC/InterActiveCorp

flag not available

Advised the Special Committee of the Board of Directors of IAC/InterActiveCorp, a leading media and internet company, on the creation of a new class of non-voting common stock 

17-Oct-16
$1.4 billion
U.S.A. flag
Target: 

Save-A-Lot

canada.gif
Acquiror: 
Affiliate of Onex Corporation

Advising SUPERVALU, Inc., one of the largest grocery wholesalers and retailers in the U.S., on the sale of its Save-A-Lot business, a leading hard-discount grocery retailer in the U.S., to an affiliate of Onex Corporation 

13-Oct-16
$NA
usa_canada.gif
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

04-Oct-16
$32.0 billion
U.S.A. flag
Target: 

Texas Competitive Electric Holdings and its subsidiaries

flag not available

Advised  Texas Competitive Electric Holdings,  Texas’ largest power generator and competitive retail electricity provider, and its subsidiaries at the direction of its independent director in connection with its and Energy Future Holdings’ Chapter 11 proceedings 

04-Oct-16
$223 million
usa_uk.gif
Target: 

U.S. rights to Toprol-XL (AstraZeneca)

canada.gif
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the U.S. rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

07-Sep-16
Pending
$NA
U.S.A. flag
Target: 

TEGNA, Inc.

flag not available

Advising TEGNA, Inc., a major broadcasting and digital marketing services company, on the spin-off of Cars.com and the creation of two independent publicly traded companies: one focused on television broadcasting and one focused on the online automotive marketplace.

18-Aug-16
Pending
$3.2 billion
switzerland.gif
Target: 

Valves & Controls Business of Pentair

U.S.A. flag
Acquiror: 
Emerson

Advising Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair

08-Aug-16
$1.5 billion
canada.gif
Target: 

Whistler Blackcomb Holdings Inc.

U.S.A. flag
Acquiror: 
Vail Resorts, Inc.

Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.

08-Aug-16
$87 million
U.S.A. flag
Target: 

Aquasana, Inc.

U.S.A. flag
Acquiror: 
A. O. Smith Corporation

Advised A. O. Smith Corporation, a leading manufacturer of residential and commercial water heaters and boilers, on the acquisition of Aquasana, a premium water treatment company, from L Catterton

28-Jul-16
$80 million
U.S.A. flag
Target: 

BioD, LLC

U.S.A. flag
Acquiror: 
Derma Sciences, Inc.

Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.

08-Jul-16
$555 million
U.S.A. flag
Target: 

New Enterprise Stone & Lime Co., Inc.

flag not available

Advised New Enterprise Stone & Lime Co., Inc. on $555 million of secured financings, including a new $450 million senior secured term loan and substantial amendments to its existing $105 million ABL revolver

28-Jun-16
$NA
israel.gif
Target: 

U.S. rights to an authorized generic version of Adderall XR

U.S.A. flag
Acquiror: 
Prasco Laboratories

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to an authorized generic version of Adderall XR

28-Jun-16
$652 million
israel.gif
Target: 

U.S. rights to 37 approved and 5 pipeline generic products

australia.gif
Acquiror: 
Mayne Pharma Group Limited

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights  to 42 generic products

Pages

show all